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Available online 15 November 2016We have examined the effects of Obstructive Sleep Apnea (OSA) on red blood cell (RBC) proteome variation at
evening/morning day time to uncover new insights into OSA-induced RBC dysfunction that may lead to OSA
manifestations. Dysregulated proteins mainly fall in the group of catalytic enzymes, stress response and redox
regulators such as peroxiredoxin 2 (PRDX2). Validation assays conﬁrmed that atmorning themonomeric/dimer-
ic forms of PRDX2 were more overoxidized in OSA RBC compared to evening samples. Six month of positive air-
way pressure (PAP) treatment decreased this overoxidation and generated multimeric overoxidized forms
associated with chaperone/transduction signaling activity of PRDX2. Morning levels of overoxidized PRDX2 cor-
related with polysomnographic (PSG)-arousal index and metabolic parameters whereas the evening level of di-
sulﬁde-linked dimer (associated with peroxidase activity of PRDX2) correlated with PSG parameters. After
treatment, morning overoxidized multimer of PRDX2 negatively correlated with fasting glucose and dopamine
levels.
Overall, these data point toward severe oxidative stress and altered antioxidant homeostasis in OSA RBC occur-
ringmainly atmorning time but with consequences till evening. The beneﬁcial effect of PAP involvesmodulation
of the redox/oligomeric state of PRDX2, whose mechanism and associated chaperone/transduction signaling
functions deserves further investigation. RBC PRDX2 is a promising candidate biomarker for OSA severity and
treatment monitoring, warranting further investigation and validation.
© 2016 Published by Elsevier B.V.Keywords:
Obstructive sleep apnea
Peroxiredeoxin-2
Red blood cells
Biomarkers1. Introduction
Obstructive sleep apnea (OSA) syndrome is a sleep-associated respi-
ratory disorder, characterized by recurrent episodes of apneas and
hypopneas during sleep with resultant intermittent hypoxia and sleep
fragmentation [1]. OSA affects about 22% of men (range, 9–37%) and
17% of women (range, 4–50%) but frequently is underdiagnosed [2].
OSA is associated with cancer [3] and cerebral, cardiovascular and met-
abolic pathologies [4], making this disorder a public health concern. The
mechanisms responsible for these outcomes are oxidative stress andca, Departamento de Genética
boa 1640-016, Portugal.
. Penque).associated inﬂammatory, autonomic, vascular, and metabolic events
[5]. The diagnosis of OSA is based on an overnight sleep exam, that
can be a laboratory polysomnography (PSG) or, in some patients, a por-
table cardio-respiratory study [6]. Presently, positive airway pressure
(PAP) devices are the ﬁrst line treatment for OSA [7] acting on
preventing obstructive episodes and thus inhibiting the cascade of del-
eterious OSA-associated pathologies. PAP improves daytime somno-
lence, cognitive function and quality of life and prevents cerebral,
cardiovascular and metabolic consequences [7]. Additionally, PAP de-
vices seem to decrease oxidative stress and inﬂammation [8,9].
The expense and time consuming nature of both sleep testing and
PAP treatment contribute to under diagnosis and consequently to
under treatment of OSA. Identiﬁcation of predictive biomarkers of OSA
concerning diagnosis, prognosis and response to treatment could be
Table 1
Cohort I - discovery phase.
Phase demographic, polysonographic and analytical characterization
Demographic and PSG parameters Screened subjects
snorer(n = 12) OSA (n = 12) p value
Age (years) 46.8 (10.0) 45.8 (7.2) NS
Habits
Current smoking (n) 6 4 NS
Current drinking (n) 7 6 NS
EPW Score 9.1 (4.3) 11.7 (6.5) NS
Observational features
Morning arterial pressure (mmHg) 141.3 (23.1)/ 129.8 (13.1)/ NS
88.8 (14.6) 78.9 (8.3)
BMI (kg/m2) 26.9 (2.7) 30.8 (1.9) 0.0002
Abdominal perimeter (cm) 97.5 (6.9) 107.4 (8.6) 0.005
Comorbidities
Hypertension (n) 6 4 NS
Respiratory diseases (n) 3 1 NS
Dyslipidemia (n) 8 10 NS
Polysomnographic parameteres
RDI (events/h) 2.7 (1.5) 41.9 (20.5) 5.96E-07
Arousal Index (events/h) 12.6 (4.8) 34.6 (18.4) 0.0003
Minimum arterial saturation (%) 87.4 (4.1) 80.5 (7.6) 0.006
T90 (%) 0.1 (0.2) 19.4 (24.6) 0.006
ODI (events/h) 3.0 (4.4) 41.2 (27.0) 3.79E-05
Sleep efﬁciency (%) 76.7 (14.1) 82.1 (6.8) NS
Analytical parameteres
Glycemic proﬁle
Glucose (70–110 mg/dl) 95.2 (8.5) 96.7 (12.0) NS
Hb A1C (4–6%) 5.7 (0.4) 5.8 (0.4) NS
Insulin (3–25 mU/l) 11.0 (6.2) 20.6 (12.5) 0.013
HOMA-IR (≥3.8) 2.6 (1.6) 5.0 (3.0) 0.012
Lipid proﬁle
Cholesterol (b190 mg/dl) 206.2 (44.3) 193.0 (30.8) NS
Triglycerides (b150 mg/dl) 127.3 (69.7) 217.1 (127.7) 0.022
Cardiovascular marker
Homocysteine (3.7–13.9 μmol/l) 15.6 (4.3) 15.1 (2.9) NS
Urinary catecholamines
Adrenalin (1.7–22.4 μg/24 h) 15.0 (15.5) 10.8 (9.3) NS
Nor-adrenalin (12.1–85.5 μg/24 h) 73.5 (34.0) 75.0 (37.4) NS
Dopamine (0–498 μg/24 h) 389.4 (218.4) 367.3 (169.5) NS
Complete hemogram
RBC (4.5–5.9 × 1012/l) 5.0 (0.4) 5.1 (0.5) NS
Hemoglobin (13–17.5 g/dl) 15.4 (0.8) 15.2 (1.6) NS
Hematocrit (40–50%) 45.9 (2.1) 45.1 (4.1) NS
MCV (80–97 ﬂ) 91.9 (6.4) 88.9 (4.1) NS
MCH (27–33 pg) 30.9 (1.8) 30.0 (1.6) NS
MCHC (31.5–35.5 g/dl) 33.6 (1.0) 33.7 (1.1) NS
RDW (11.5–14.5) 13.4 (0.7) 13.5 (0.9) NS
Leukocytes (4.0–11 × 109/l) 6.7 (1.2) 7.8 (2.3) NS
Platelets (150–450 × 103 μl) 237.8 (40.1) 261.7 (77.2) NS
NS: non-statistical meaning.
EPW: Epworth Sleepiness Scale; BMI: body mass index; RDI: respiratory disturbance
index; T90%: time spent with saturation b 90%; ODI: oxygen desaturation index; HbA1C:
hemoglobi n glycated; HOMA-IR: model assessment of insulin resistance; RBC: red
blood cells; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin;
MCHC: mean corpuscular hemoglobin; RDW: red cell distribution width.
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covery, such as advanced proteomics-based technologies, have gained
importance in several pathologies, including OSA [10]. By using two-di-
mensional ﬂuorescence difference gel electrophoresis (2-D DIGE) -
based proteomics, we intended herein to investigate for the ﬁrst time
to our knowledge OSA red blood cell (RBC) proteome at two time
points, before and after one night of sleep. Dysfunction in the RBC ho-
meostasis has been described as a potential source of systemic inﬂam-
mation that leads to metabolic diseases, such as obesity, insulin
resistance and hypertension [11]. These disorders are also recognized
as OSA associated sequelae [1,4,5]. The RBC redox-state may also play
an important role in the physiology of circadian rhythms [12] and sleep-
lessness, hypoxia or oxidative-stress induced circadian disruption that
may lead to tumorigenesis and metabolic syndrome [13,14]. Therefore,
we are convinced that studies focused on the identiﬁcation of dysregu-
lated proteins in OSA RBC, before or after nocturnal intermittent hypox-
ia and sleep disruption could provide new insights into underlying
pathological mechanisms and uncover new candidate biomarkers of
OSA and OSA associated disorders. Additionally, studies evaluating the
effect of PAP treatment in themodulation of these proteinswill contrib-
ute to better understanding and monitoring of the effectiveness and/or
side-effects of PAP therapy.
2. Material and methods
2.1. Patients
One hundred four consecutive male subjects with clinically
suspected OSA syndrome were screened and evaluated through inter-
views for inclusion in this study. Before PSG study, all subjects
underwent a restricted diet during three days, including no drugs to in-
duce sleep. The PSGwas performed overnight at the sleep laboratory ac-
cording to standard procedures [6]. After diagnosis, PAP therapy with
automatic devices (S9, Resmed, Australia) were prescribed for patients
with OSA severe disease (respiratory disturbance index (RDI) ≥ 30/h)
or with any severity (RDI ≥ 5/h)when associatedwith excessive diurnal
sleepiness and/or cardio or cerebro vascular complications (hyperten-
sion, arrhythmia, coronary disease, cerebral or cardiac stroke) as de-
scribed [15].
Patients were selected to participate in two phases of the study,
namely discovery and validation phase. For the discovery phase, 12 sub-
jects diagnosed with primary snoring (RDI b 5/h) and 12 subjects with
moderate (RDI ≥ 15/h, but b30/h) (n= 5) or severe OSA (RDI ≥ 30/h)
(n= 7) were selected (Cohort I, Table 1). For validation phase, 10 sub-
jects with primary snoring (RDI b 5/h) and 10 subjects with mild
(RDI ≥ 5/h, but b15/h) (n = 4) or moderate to severe OSA (RDI ≥ 15/
h) (n = 6) that underwent six month of PAP treatment were selected
(Cohort II, Table 2). Exclusion criteria were female gender (to avoid hor-
monal inﬂuence), shift workers, other sleep disorders, neuromuscular
disease, heart failure, diabetes, neoplasia, acute disease and previous
PAP treatment.
2.2. Sample collection & biochemical analysis
At the day of hospitalization, 24 h urine was collected for catechol-
amine determination, according to the hospital standard procedures.
Blood samples were collected into EDTA-coated polypropylene tubes
before and after PSG i.e., between 8:00 pm and 09:30 pm (referred to
as ‘evening’) and between 7:30 am and 09:00 am.
(referred to as ‘morning’). Patients who underwent PAP treatment, a
second blood sample was collected after six months of treatment under
the same conditions as above described but at morning time only. He-
matological and metabolic analyses were immediately performed on
morning samples according to the hospital procedures. For proteomics
study, samples were kept no longer than 4 h at 4 °C until fractionation.The obtained RBC pellets were aliquoted and stored at −80 °C until
analysis.
2.3. 2D-DIGE based proteomics discovery phase
RBC sample preparation, analysis by 2D-DIGE approach followed by
mass spectrometry for protein identiﬁcation and protein annotation
and classiﬁcation using dedicated bioinformatics tools are described in
detail in [16].
2.4. Validation phase
The validation of proteomics data was performed for peroxiredoxin
2 (PRDX2) on samples from Cohort II (Table 2).
Table 2
Cohort II - validation phase.
Demographic, polysonographic and analytical characterization
Demographic and PSG parameters Screened subjects
Snorer (n = 10) OSA (n = 10) PAP (n = 10) p value Snorer vs OSA p value OSA vs PAP
Age (years) 43.6 (11.9) 43.0 (7.1) – NS NS
Habits
Current smoking (n) 4 2 – NS n/a
Current drinking (n) 5 6 – NS n/a
EPW score 11.7 (4.8) 11.5 (4.5) 6.6 (4.7) NS 0.0003
Observational features
Morning arterial pressure (mmHg) 138.6 (21.7)/85.1 (13.5) 124.2 (18.3)/77.8 (12.3) – NS n/a
BMI (kg/m2) 27.5 (3.9) 29.6 (2.3) – NS n/a
Abdominal perimeter (cm) 98.0 (9.3) 105.0 (8.8) – NS n/a
Comorbidities
Hypertension (n) 5 5 – NS n/a
Respiratory diseases (n) 0 0 – NS n/a
Dyslipidemia (n) 7 7 – NS n/a
Polysomnographic parameteres
RDI (events/h) 3.3 (1.2) 34.8 (26.5) – 0.001 n/a
Arousal index (events/h) 12.8 (4.8) 34.7 (19.8) – 0.002 n/a
Minimum arterial saturation (%) 87.4 (3.4) 81.0 (7.4) – 0.012 n/a
T90 (%) 0.1 (0.1) 12.6 (19.5) – 0.028 n/a
ODI (events/h) 5.2 (5.9) 28.8 (27.4) – 0.008 n/a
Sleep efﬁciency (%) 79.8 (14.3) 80.4 (12.7) – NS n/a
PAP record
Number of days without use – – 54.4 (63.7) – n/a
Total of recording days – – 200.0 (21.5) – n/a
Use per night (min) – – 269.7 (123.4) – n/a
Residual AHI (events/h) – – 1.6 (1.1) – n/a
Analytical parameteres
Glycemic proﬁle
Glucose (70–110 mg/dl) 96.1 (8.1) 95.1 (11.9) 95.3 (11.2) NS NS
Hb A1C (4–6%) 5.6 (0.4) 5.7 (0.4) 5.7 (0.3) NS NS
Insulin (3–25 mU/l) 11.5 (6.9) 20.7 (13.5) 28.9 (40.9) 0.036 NS
HOMA-IR (≥3.8) 2.8 (1.8) 5.0 (3.2) 7.2 (10.8) 0.036 NS
Lipid proﬁle
Cholesterol (b190 mg/dl) 200.9 (39.8) 181.1 (23.6) 178.9 (28.1) NS NS
Triglycerides (b150 mg/dl) 128.5 (70.7) 169.6 (90.7) 153.4 (69.9) NS NS
Cardiovascular marker
Homocysteine (3.7–13.9 μmol/l) 14.7 (4.3) 14.1 (2.8) 15.4 (2.0) NS NS
Urinary catecholamines
Adrenalin (1.7–22.4 μg/24 h) 17.3 (15.3) 9.9 (9.1) 20.0 (7.7) NS 0.010
Nor-adrenalin (12.1–85.5 μg/24 h) 56.9 (15.9) 64.1 (36.9) 54.3 (25.6) NS NS
Dopamine (0–498 μg/24 h) 301.7 (117.7) 244.8 (105.5) 258.8 (123.3) NS NS
Complete hemogram
RBC (4.5–5.9 × 1012/l) 5.0 (0.5) 5.1 (0.4) 4.9 (0.3) NS 0.018
Hemoglobin (13–17.5 g/dl) 15.4 (0.9) 15.5 (1.2) 15.1 (1.0) NS 0.041
Hematocrit (40–50%) 45.7 (2.4) 45.7 (3.3) 44.1 (3.1) NS 0.008
MCV (80–97 ﬂ) 91.5 (5.3) 89.5 (3.3) 89.7 (3.4) NS NS
MCH (27–33 pg) 30.7 (1.2) 30.2 (1.3) 30.7 (1.2) NS NS
MCHC (31.5–35.5 g/dl) 33.6 (1.1) 33.8 (0.9) 34.3 (0.8) NS 0.051
RDW (11.5–14.5) 13.3 (0.5) 13.2 (0.9) 13.8 (0.6) NS 0.030
Leukocytes (4.0-11 × 109/l) 7.1 (1.0) 7.6 (1.8) 7.2 (1.8) NS NS
Platelets (150–450 × 103 μl) 241.5 (31.1) 238.5 (46.2) 203.4 (47.8) NS 0.012
NS: non-statistical meaning; n/a: not-applicable.
EPW: epworth sleepiness scale; BMI: bodymass index; RDI: respiratory disturbance index; T90%: time spentwith saturation b 90%;ODI: oxygen desaturation index; AHI: apnea-hypopnea
index; HbA1C: hemoglobin glycated; HOMA- IR: model assessment of insulin resistance; RBC: red blood cells; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin;
MCHC: mean corpuscular hemoglobin; RDW: red cell distribution width.
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followed bywestern blotting (WB) using 1:20,000 rabbit anti-PRDX2 or
1:3000 rabbit anti- PRDX-SO2/3 antibody (Ab; Abcam) to investigate
PRDX-2 redox-oligomeric state as described [17]. Before lyses,
100 mM of N-ethylmaleimide (NEM) was added to the samples to pre-
vent exogenous-induced oxidation [17].
2.5. Statistical analysis
Descriptive analyses for clinical and analytical data were expressed
as mean ± standard deviation (SD), and frequency (% values) was
used to characterize the groups. One-way ANOVA (analysis of variance)
was used to compare statistically more than two groups; Paired Stu-
dent-t-test was used to compare evening and morning condition inthe same group set (Snorer or OSA), and to evaluate the effect of (be-
fore/after) PAP treatment in OSA group set. Student-t-test for indepen-
dent sampleswas used to compare Snorer andOSA groups at evening or
morning condition. Correlation of variables was carried out using Pear-
son Correlation test. The level of statistical signiﬁcance was set at 5% (p-
value b 0.05).
3. Results
3.1. Patients: clinical, biochemical and metabolic characteristics
Results are summarized in Tables 1 and 2. In both, Cohort I (Discov-
ery phase) and Cohort II (Validation phase), signiﬁcant differenceswere
observed regarding the PSG parameters and the insulin and insulin
624 A. Feliciano et al. / Biochimica et Biophysica Acta 1863 (2017) 621–629resistance, determined by homeostatic model assessment of insulin re-
sistance (HOMA-IR) levels, which are higher in OSA patients compared
with Snorers (p b 0.05 Student t-test). No signiﬁcant differences were
observed for the other parameters, except that in Cohort I, signiﬁcant
differences were observed in the body mass index (BMI) and triglycer-
ides level, both were higher in OSA patients compared to Snorers (Stu-
dent t-test, p b 0.05) (Table 1). No signiﬁcant differences were found in
these parameters between OSA and Snorer groups participating in Co-
hort II (Table 2).
After six month of PAP treatment (compliance with mean usage N4
h.night−1), patients reported a signiﬁcant decrease in excessive day-
time somnolence, evaluated by the Epworth Sleepiness Scale (EPW)
score (Paired Student t-test, p b 0.05) (Table 2).
The urinary catecholamine, adrenalin, was signiﬁcant higher, while
no differences were observed for nor-adrenaline and dopamine after
treatment. The Hemogram data, although showing clinical normal ref-
erence values, it revealed a small, but signiﬁcant, decrease in the RBCs
and platelets count, haemoglobin concentration and hematocrit in pa-
tients after PAP treatment. The mean corpuscular hemoglobin (MCH)
and red cell distribution width (RDW) were signiﬁcantly higher in re-
sponse to treatment (Paired Student t-test, p b 0.05). There were no sig-
niﬁcant changes in glucose and lipid proﬁle and cardiovascular marker
after treatment (Table 2).
3.2. Day or night variations in OSA RBC proteome
950 protein spots were visualized on 2DIGE images. 76 of these ex-
hibited signiﬁcant differences in abundance (fold change ≥ 1.2; Anova
p b 0.05) between OSA and Snorer's at evening or morning times (Fig.
1 - Data in Brief [16]).
From these spots, 31 were identiﬁed by MS, corresponding to 21
unique proteins suggesting the existence of post-translationalmodiﬁca-
tion (PTM) regulations (Table 1-Data in Brief [16]).
Someof these proteins/proteoforms showed abundance changes ex-
clusively in OSAmorning or OSA evening compared with the ones from
Snorers or between morning and evening whatever is OSA or Snorers
(Fig. 2-Data in Brief [16]). Functional analysis by DAVID Bioinformatics
Resources [18] showed that most identiﬁed proteins are associated
with catalytic, oxidoreductase, peroxidase, hydrolase, ATPase and anti-
oxidant activity and nucleoside binding. Concerning biological process,
OSAmorning differential proteinsweremainly associatedwith negative
regulation of metabolic, cellular and biological processes and response
to chemical stimulus. OSA evening differential proteins were mostly as-
sociated with positive regulation of catalytic activity and molecular
function and catabolic and metabolic process. Morning compared with
evening in OSA showed a larger numbers of differential proteins thus
a larger number of associated biological processes, which included1
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Fig. 1. 2DIGE referencemap of Hb-depleted RBC fromOSA and Snorers patients collected at even
and indicated with circles on the 2D–gel reference image displayed on the left. Their identity is
showing signiﬁcantly higher levels of abundance in OSA morning samples as shown on the rigresponse to chemical stimulus, oxidation reduction, regulation of cata-
lytic activity and response to stress (Fig. 2-Data in Brief [16]).
3.3. Peroxiredoxin-2 redox/oligomeric states in OSA RBC
Acidic PRDX-2 spot, reported as hyper/oxidized proteoforms of
PRDX2 [17] was one of those proteins identiﬁed higher abundant in
2DIGE maps of OSA morning samples (Anova p b 0.05) compared to
the ones from Snorers (Fig. 1).
To validate whether the redox/oligomeric states of PRDX-2 are dif-
ferentially modulated in OSA as indicated by the proteomics data, sam-
ples were analysed by a non-reducing WB using an antibody (Ab)
against PRDX2 or against sulphinylated/sulfonylated (−SO2/3H) forms
of PRDXs (PRDXSO2/3) [17]. A new Cohort of Snorer and OSA patients,
before and after six month of PAP treatment, was used (Table 2).
As illustrated in Fig. 2A, in non-reducing SDS-PAGE condition, dimer
or multimer of PRDX2 present in cells that are fully reduced or fully
overoxidized are denatured and visualized as ~21 kDa monomers by
WB using Ab-PRDX2. In contrast, dimeric/multimeric oxidized forms
that have two disulﬁdes (S-S/S-S) linked peroxidatic cysteins or one di-
sulﬁde linked whereas the other is either reduced or overoxidized (S-S/
SH or S-S/SO2H) are denatured and visualized as ~50 kDa (denominated
here as S-S/S-S dimer) and 52KDa (S-S dimer), respectively [19].
Multimers fully or partially disulﬁde linked (N200 kDa) that are not de-
natured are also eventually observed [17]. However, the short exposure
timeused tominimizeﬁlm saturation (WBdetection), limited visualiza-
tion and quantiﬁcation of multimeric forms detected by the Ab-PRDX2
antibody. Using the Ab-PRDXSO2/3 on RBC lysates analysed by a non-re-
ducing SDS-PAGE condition, PRDX2 that contain sulphinylated (SO2H)
cysteins is exclusively detected [20].
The WB results using Ab-PRDX2 showed higher abundance of
PRDX2 monomers in OSA morning compared to the ones from Snorers
(Figs. 3A and 4A). After PAP treatment, these levels were much in-
creased (Fig. 4A). The WB using Ab-PRDXSO2/3 conﬁrmed that the
higher levels of PRDX2 monomers in OSA were mostly overoxidized
(Figs. 3B and 4B). Interestingly, the increased levels of PRDX2 mono-
mers after PAP treatment might mostly correspond to reduced forms
since their overoxidation level showed signiﬁcant decrease after treat-
ment (Fig. 4B).
In OSA, although themorning level of PRDX2monomer was not sig-
niﬁcantly different compared with evening, its overoxidation level was
higher than evening (Fig. 3B). In Snorers, the amount of PRDX2 mono-
mer as its overoxidation level were, in contrast, signiﬁcantly lower in
morning compared with evening ones (Fig. 3B).
In OSA, the level of evening PRDX2 S-S/S-S oxidized dimer presented
a tendency, although not signiﬁcant, to be slightly higher compared
with Snores ones, corroborating our Proteomics data (spot 19 in Fig. 1- 20kDa
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via thioredoxin(TRX)/NADPH system. Peroxidase activity of 2-Cys PRDXs is not only for oxidant defence but also for H2O2 signaling sensing and/or transduction. In presence of high
levels of H2O2, 2-Cys PRDX undergoes a non-peroxidase catalytic cycle or sulphinic (SO2H) or overoxidized cycle that is recycled to active enzyme by sulﬁredoxin in the presence of
ATP. Reversible oxidation is coupled to circadian rhtythm to 2-Cys PRDX function. Overoxidation of 2-Cys PRDXs allows substantial accumulation of H2O2 for signalling purposes or to
confer chaperone function to 2-Cys PRDX under severe oxidative stress. Chaperone activity is attributted to multimeric decameric rings of 2Cys-PRDXs.
625A. Feliciano et al. / Biochimica et Biophysica Acta 1863 (2017) 621–629and Table 1- Data in Brief [16]). The level of dimeric S-S form detected
by Ab-PRDX2 showed no signiﬁcant differences between OSA and
Snorers whatever was evening or morning (Fig. 3A). However, higherlevel of S-S/SO2 dimeric forms detected by Ab-PRDX SO2/3 was observed
in OSA compared to Snorers (Fig. 3B). Interesting, these higher levels of
S-S/SO2 dimer at morning decreased signiﬁcantly after PAP treatment
Ab PRDX2
Ab PRDXSO2/3
A
B
Fig. 3.Western blot validation of 2DIGE proteomics data indicating redox/oligomeric changes in the PRDX2 from OSA evening/morning RBC versus Snorers'. Representative western blots
(on the left) of non-reducing SDS-PAGE incubatedwith Ab PRDX2 (A) or Ab PRDXSO2/3 (B) and graphic representations (on the right) of the relative normalized protein abundance of the
different redox/oligomeric forms of PRDX2 identiﬁed in the different groups/conditions [Snorers (S) or OSA/evening (E) or morning (M)] calculated from densitometric analysis (see
Material & methods). Statistically signiﬁcant differences (p b 0.05) between groups/conditions are indicated (*).
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were also detected mostly exclusively in OSA patients that underwent
six month of PAP treatment (Fig. 4B).
3.4. PRDX2 correlation with OSA clinical parameters
The correlation between the different redox/oligomeric state of
PRDX2 at evening or morning time and PSG and biochemical variables
were studied. To facilitate interpretation, Table 3 showed the correla-
tions obtained for S-S/S-S dimer and overoxidized (SO2) monomers
and overoxidized (S-S/SO2) dimer, since they are unequivocally associ-
atedwith peroxidase catalytic cycle and non-peroxidase (overoxidized)
cycle of PRDX2, respectively as represented in Fig. 3B. At evening, the
level of S-S/S-S dimer positively correlated to the PSG parameters
[RDI, oxygen desaturation index (ODI) and time spent with saturation
b90% (T90%)] whereas the level of SO2monomer or S-S/SO2 dimer neg-
atively correlated to RDI, ODI and diurnal oximetry (Table 3).
In morning samples, the level of SO2 monomer positively correlated
with PSG-Arousal Index while the level of S-S/SO2 dimer positively cor-
related with glucose metabolism parameters (HbA1C, insulin and
HOMA-IR) and negatively with minimum oxygen saturation. No corre-
lationwas observed formorning level of S-S/S-S dimerwith clinical var-
iables under study (Table 4). After PAP treatment, the level of morning
overoxidized monomer and dimer positively correlated with triglycer-
ides. Overoxidized dimer and multimer negatively correlated withdopamine and fasting glucose parameters and positively with MCH he-
matological parameter (Table 4).
4. Discussion
This study examined for the ﬁrst time the effect of OSA on the RBC
proteome homeostasis, which dysregulation may lead to OSA severity
and outcomes. Samples collected at two time points (‘evening’ and
‘morning’), i.e., before and after night PSG, were investigated by
2DIGE-based proteomics. Proteins/proteoforms associated with RBC
stress response and antioxidant regulatory system were the most
changed in OSA compared with Snorers when investigated in evening
ormorning samples [16]. Since RBCs are devoid of any translational ma-
chinery, these day-night changes might result from PTM regulations.
PRDX2, a member of six thiol peroxidases playing a key role in the
antioxidant defense and redox signaling [17], is one of those proteins
changed in OSA RBC. PRDX2 is the third most abundant protein in
RBC, which circadian redox events has been reported as involved in
the mechanism for timekeeping [21]. PRDXs have been demonstrated
to regulate several diseases related to redox-dependent process [22].
Modulations in the redox state or oligomeric structure of PRDXs can
have a signiﬁcant impact on their function and thus in the signaling cas-
cades of events in which it participates [21]. In our proteomics study,
acidic forms of PRDX2 described as overoxidized [17] were signiﬁcantly
increased in OSA morning RBCs.
Ab PRDX2
Ab PRDXSO2/3
A
B
Fig. 4. Effect of six month of PAP treatment on the redox/oligomeric state of PRDX2 from morning RBC. Representative western blots images (on the left) of non-reducing SDS-PAGE
incubated with Ab PRDX2 (A) or Ab PRDXSO2/3 (B) and graphic representations (on the right) of the relative normalized protein abundance of the different redox/oligomeric forms of
PRDX2 identiﬁed in the different patients group (Snorers (S), OSA before and after PAP (P) calculated from densitometric analysis (see Material & methods). Statistically signiﬁcant
differences (p b 0.05) between groups/conditions are indicated (*).
Table 3
Correlation of redox/oligomeric state of PRDX2 to PSG and metabolic variables under
study.
Evening Morning
PRDX2 Correlate Pearson r
value
p
value
Correlate Pearson r
value
p
value
S-S/S-S
dimer
RDI 0.633⁎ 0.049 No signiﬁcant correlation
observed
RDI 0.633⁎ 0.049
ODI 0.657⁎ 0.039
T90% 0.727⁎ 0.017
SO2
monomer
RDI −0.399 0.081 PSG-arousal
index
0.482⁎ 0.031
RDI −0.399 0.081
ODI −0.474⁎ 0.035
Diurnal
oximetry
−0.823⁎⁎ 0.000
S-S/SO2
dimer
Diurnal
oximetry
−0.467⁎ 0.038 Min O2
saturation
−0.586⁎⁎ 0.007
Hb A1C 0.452⁎ 0.045
Insulin 0.448⁎ 0.048
HOMA-IR 0.448⁎ 0.048
RDI, respiratory disturbance index; ODI, oxygen desaturation index; T90%, the time spent
with saturation b 90%; PSG, polysomnography; Min O2 saturation, minimum oxygen sat-
uration HbA1C, glycated hemoglobin; HOMA-IR, homeostatic model.
⁎⁎ Correlation is signiﬁcant at the 0.01 level (2-tailed).
⁎ Correlation is signiﬁcant at the 0.05 level (2-tailed).
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ical 2-Cys PRDX, the PRDX2 peroxidatic cystein of one subunit reacts
with hydrogen peroxide (H2O2) and is oxidized to sulfenic acid deriva-
tives (-SOH) that form a disulﬁde (-S-S-) bound with the resolving
cystein of another subunit. Oxidized dimeric form is subsequently re-
duced by thioredoxin (Trx) system to enable further peroxidase catalyt-
ic cycle of H2O2. Occasionally andwith increasingH2O2 concentration, 2-
Cys PRDXs can be overoxidized to sulphinic and sulphonic acids (Cp-Table 4
Correlation of redox/oligomeric state of PRDX2 to metabolic variables under study after
PAP treatment.
PRDX2
Morning
Correlate Pearson r value p value
SO2 monomer Fasting glucose −0.810⁎⁎ 0.005
Triglycerides 0.713⁎ 0.021
S-S/SO2 dimer Triglycerides 0.770⁎⁎ 0.009
Dopamine −0.666⁎ 0.035
SO2 multimer Fasting Glucose −0.842⁎⁎ 0.002
Dopamine −0.697⁎ 0.025
MCH 0.713⁎ 0.021
MCH, mean corpuscular hemoglobin.
⁎⁎ Correlation is signiﬁcant at the 0.01 level (2-tailed).
⁎ Correlation is signiﬁcant at the 0.05 level (2-tailed).
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plained by the “ﬂoodgate” hypothesis [23]. Overoxidation to sulphinic
acids may then be recycled to peroxidatic active forms by sulﬁredoxin
in an ATP-dependent reaction [17]. These two alternative catalytic cy-
cles of 2-Cys PRDXs, the peroxidase one and the non-peroxidase, i.e.,
the sulphinic acid (overoxidized) one, involves dramatic changes in its
quaternary structure and function (Fig. 2B). Reduced 2-Cys PRDXs can
exist as decamer or dodecamer forms and dynamically exchange sub-
units with cellular pool. Upon oxidation, decamer dissociates into di-
mers to recover peroxidase activity through Trx-reduction recycling.
Overoxidation and probably other PTMs interfere with subunit ex-
change and stabilized the decameric structure into higher-order of
multimerization [24]. Reversible overoxidation of 2-Cys PRDXs has
been seem as an evolutionary adapted mechanisms to allow H2O2-de-
pendent cell signaling purposes, circadian rhythm to PRDXs recycling/
function and chaperone function in response to severe oxidative stress
[25].
To investigate whether the redox-oligomeric state of PRDX2 is dif-
ferentially modulated in OSA RBC as indicated by our proteomics data,
we performed non-reduced WB assays on these cells using AbPRDX2
andAb-PRDXSO2/3. The data conﬁrmed our proteomics results by show-
ing that in morning samples the level of both PRDX2 monomers and
dissulﬁde linked (S-S) dimers resulting from fully and/or partially
overoxidized dimers/oligomers, respectively, were signiﬁcantly in-
creased and higher overoxidized to SO2H acid in OSA compared to
Snorers. Evidence from human studies has shown that untreated OSA
causes oxidative stress [5]. Therefore, our ﬁndings strongly suggest
that in OSA RBC the higher overoxidation of PRDX2 at morning might
be a consequence of overnight hypoxia/sleep fragmentation-induced
oxidative stress response.
Although between morning and evening the level of overoxidized
PRDX2monomer changed in bothOSA and Snorers, probably a behavior
coupled to circadian rhythm, in OSA, the level of this overoxidized form
was higher in morning than evening, while in Snorers the opposite was
observed, i.e., much lower in morning than evening. Whether this
change in OSA causes or results from an imbalance in the circadian sys-
tem of PRDX2, need to be investigated.
The evening level of PRDX2 S-S/S-S dimer positively correlated with
OSA PSG diagnostic parameters such as RDI, ODI and T90%while morn-
ing levels of overoxidized forms showed negative correlationwith some
of these PSG parameters (Table 3). Since this dimeric form results from
peroxidase enzymatic activity of the protein (Fig. 2B), these data sug-
gest that at evening the peroxidase cycle of PRDX2 predominates in
OSA and is associated with OSA severity.
At morning, no correlation was found for S-S/S-S dimer to any clini-
cal parameters. However, the level of PRDX2 SO2 monomer showed
positive correlation with PSG-arousal index while S-S/SO2 dimer
showed positive correlation with metabolic parameters such as
HbA1C, insulin and HOMA-IR (Table 3). These data suggest that at
morning the non-peroxidase (overoxidation) cycle of PRDX2 predomi-
nates in OSA and is mainly associated with the metabolic status of the
patients.
In RBCs, the circadian oscillation of PRDX2 overoxidation is deter-
mined by hemoglobin autoxidation [20]. Oxidative stress can induce oxi-
dative PTMs in hemoglobin [26]. PRDX2 bind and stabilize hemoglobin
against excessive oxidative stress-induced aggregation [27]. High levels
of plasma glucose produce glycated hemoglobin (HbA1C), amarker of di-
abetes progression, making hemoglobin more amenable to oxidation
[28]. Although not diagnosed as diabetics, OSA patients in this study pre-
sented higher level of insulin and HOMA-IR compared to Snorers. The
HbA1C levels correlated positively (r=0.561, p=0.01)with the glucose
levels in these patients (data not shown). This pre-diabetic condition as-
sociated with OSA-induced oxidative stress might explain the correlation
of morning level of RBC PRDX2 overoxidation with glycemic indicators.
Differential associations of circulating PRDXs (PRDX1,2,4 and 6)
levels with indicators of glycemic control and triglycerides in type 2diabetes mellitus have been reported [29,30]. However, intracellular
PRDX2 is a peroxidase and chaperone/transduction signaling protein
whereas plasma PRDX2 that is stress-induced secreted from different
cells such as activated macrophages presented chemokine-like actions
enabling induction of inﬂammatory responses [31]. More studies will
be needed to better deﬁne the role(s) of PRDX2 proteoforms in different
cells and subcellular location under disease associated with redox im-
balance oxidative condition such as OSA and OSA-associated metabolic
disorders.
The existence of morning RBC samples of OSA patients after six
months of PAP treatment allowed us to investigate the therapeutic ef-
fect of PAP in the modulation of RBC PRDX2 at least, at this day time.
After treatment, the morning higher level of overoxidation of both
PRDX2 SO2 monomer as S-S/SO2 dimer showed a signiﬁcant decrease.
Since the total level of PRDX2 monomers showed increases after PAP
the decrease in its overoxidation state might be followed by an increase
of reduced (-SH) forms of the protein. Interesting, however was that,
overoxidized (SO2) multimer of PRDX2 (N200 kDa) was identiﬁed al-
most exclusively in the majority OSA patients after PAP treatment and
in two Snorers patient's controls. Multimeric overoxidized PRDXs is as-
sociated with chaperone function, although chaperone function can be
independently modulated by protein PTM regulation. Any redox state
ormultimeric structure of PRDXs is also associated with redox signaling
functions of the protein [17].
The therapeutic effect of PAP in the reduction of PRDX2
overoxidation associated with putative activation of chaperone and/or
transduction signaling function of PRDX2 as suggested by theseﬁndings
warrants further investigation of its mechanisms of action and its rela-
tion with oxidative stress and/or inﬂammation control by PAP
treatment.
After PAP treatment, the morning level of RBC overoxidized PRDX2
multimer negatively correlated with the level of serum glucose and
urine catecholamine dopamine (Table 4). OSA-induced sympathetic ac-
tivity following an increased catecholamines secretion is associated
with cardiovascular disorders and disturbance in glucose metabolism
[32]. The effects of PAP on sympathetic activity and glucose homeostasis
control are still debated [33,34]. In this study, although no signiﬁcant
changes in the catecholamine and glycemic proﬁles were observed
after PAP, except in adrenalin that slightly increased after treatment,
the level of dopamine positively correlated (r = 0.796, p = 0.006)
with glucose level after PAP (data not shown).
Interestingly, RBCs are capable of transport, accumulation and
metabolization of catecholamines, whose biological signiﬁcance re-
mains unclear [35]. Under physiological conditions catecholamines,
in particular dopamine, are higher concentrated in RBCs than in
plasma via an active transport regulated by insulin [36]. The putative as-
sociation of RBC PRDX2 to this process as suggested by its positive cor-
relation with insulin and negative correlation with dopamine and
glucose in OSA before and after PAP, respectively, deserves further
elucidation.
There are some limitations of this study. Sample size, female gender
exclusion, OSA group constituted by non-diabetics with higher levels of
blood insulin and HOMA-IR and Snorers group constituted by non-
completely healthy subjects limit the data generalization. Although pa-
tients were instructed to follow a restricted diet for three days before
urine/blood collection to minimize its impact in patient's antioxidant
status and catecholamine determination, their dietary habits were not
fully controlled. The evaluation of two time points (evening and morn-
ing) can provide important insights to a sleep disease like OSA but
are not sufﬁcient to study circadian rhythmicity of protein expression
or activity. Since no evening samples were collected after treatment,
further studies on PRDX2 redox-oligomeric state at this day time
will be necessary to complete the data. Proteomics and validation
analysis were performed on−80 °C stored samples, which could intro-
duce some bias in the molecular events of both control and disease
samples.
629A. Feliciano et al. / Biochimica et Biophysica Acta 1863 (2017) 621–6295. Conclusions
In summary, the present ﬁndings demonstrated evening and morn-
ing differential alterations in OSA RBC proteome probably in conse-
quence of nocturnal apnea-induced intermittent hypoxia/sleep
disruption experienced by these patients. The antioxidant defense
and/or redox-signaling involving PRDX2 seemed highly modulated
and correlated with OSA severity and/or metabolic status of the pa-
tients. The observed proteome changes point toward oxidative stress
and/or decreased antioxidant capacity in OSA mainly at morning time
butwith consequences along the day. Sixmonths of PAP signiﬁcantly in-
creased chaperone/transduction signaling function of RBC PRDX2 that
might be linked with beneﬁcial effects of PAP in improving oxidative-
stress and metabolic status of the patients. The redox/oligomeric state
of RBC PRDX2 is promising candidate biomarker for OSA disease sever-
ity and PAP therapeutic management that warrants further investiga-
tion and validation in larger population.
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